Why Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rose 8.7% on Sep 2, 2026
The clearest new catalyst: ESC Congress clinical data presentations.
Why did ALNY stock rise?
Alnylam Pharmaceuticals rose 8.7% on September 2, 2026, driven by positive clinical data presentations at the European Society of Cardiology Congress, where the company showcased expanded HELIOS-B and Amvuttra data demonstrating the strength of its RNAi-powered TTR silencing approach across ATTR-CM patient populations. The data reinforced analyst confidence in pipeline candidates nucresiran and TRITON-CM, with major investment firms reaffirming bullish ratings and easing prior investor concerns from summer market turbulence.
- ESC Congress clinical data presentations: Alnylam presented expanded HELIOS-B and Amvuttra data at the European Society of Cardiology Congress 2026, demonstrating the efficacy of its RNAi-powered TTR silencing approach across ATTR-CM (transthyretin amyloid cardiomyopathy) patient populations.
- Analyst reaffirmations and bullish commentary: Major investment firms including Barclays and H.C. Wainwright reaffirmed Buy ratings, with commentary highlighting upcoming trial milestones for nucresiran and durable long-term adoption potential in high-prevalence cardiovascular indications.
- Relief from prior summer concerns: The positive data and analyst support eased investor anxieties regarding competition and recent guidance adjustments that had weighed on the stock earlier in the summer.
Initial detection
BestStocks first flagged ALNY intraday on Sep 2, 2026; this analysis was finalized after the close using the confirmed +8.7% session move and additional catalyst research.
Show the initial intraday note
Alnylam Pharmaceuticals surged +9.18% to $268.71 following positive clinical data presentations at the European Society of Cardiology (ESC) Congress 2026, according to the web_catalyst. The company showcased expanded HELIOS-B and Amvuttra data demonstrating strength of its RNAi-powered TTR silencing across ATTR-CM patient populations, reinforcing analyst outlooks for pipeline candidates nucresiran and TRITON-CM and easing prior investor concerns from earlier summer turbulence. Volume of 947,294 shares traded 1.66x normal levels for this point in the session.
What to watch next: Alnylam Pharmaceuticals earnings scheduled for 2026-10-29 (consensus EPS estimate $1.79); any management commentary on TTR pipeline advancement and competitive positioning versus rival ATTR therapies.
Frequently asked questions
Why did Alnylam Pharmaceuticals, Inc. (ALNY) stock rise on Sep 2, 2026?
Alnylam Pharmaceuticals rose 8.7% on September 2, 2026, driven by positive clinical data presentations at the European Society of Cardiology Congress, where the company showcased expanded HELIOS-B and Amvuttra data demonstrating the strength of its RNAi-powered TTR silencing approach across ATTR-CM patient populations. The data reinforced analyst confidence in pipeline candidates nucresiran and TRITON-CM, with major investment firms reaffirming bullish ratings and easing prior investor concerns from summer market turbulence.
How much did ALNY stock rise on Sep 2, 2026?
ALNY rose 8.7% during the Sep 2, 2026 trading session.
What were the main drivers behind ALNY's move?
ESC Congress clinical data presentations; Analyst reaffirmations and bullish commentary; Relief from prior summer concerns.